Fluoroquinolone-and ceftriaxone-based therapy of community-acquired pneumonia in hospitalized patients: The risk of subsequent isolation of multidrug-resistant organisms

American Journal of Infection Control

Volumn 42, Issue 5, 2014, Pages 539-541

  Goldstein, Robert C ^a   Husk, Gregg ^a   Jodlowski, Tomasz ^a   Mildvan, Donna ^a   Perlman, David C ^a   Ruhe, Jörg J ^a  

^a BETH ISRAEL MEDICAL CENTER   (United States)

Author keywords

Antibiotic resistance; Community acquired pneumonia; Treatment

Indexed keywords

AZITHROMYCIN; CEFTRIAXONE; MOXIFLOXACIN; ANTIINFECTIVE AGENT; QUINOLONE DERIVATIVE;

ADULT; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; CHARLSON COMORBIDITY INDEX; CLOSTRIDIUM DIFFICILE; COHORT ANALYSIS; COMMUNITY ACQUIRED PNEUMONIA; COMORBIDITY; CONTROLLED STUDY; FEMALE; HOSPITAL PATIENT; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MORTALITY; RETROSPECTIVE STUDY; VANCOMYCIN RESISTANT ENTEROCOCCUS; ADOLESCENT; BACTERIA; COMMUNITY-ACQUIRED INFECTIONS; DRUG EFFECTS; ISOLATION AND PURIFICATION; MIDDLE AGED; MULTIDRUG RESISTANCE; PNEUMONIA, BACTERIAL; RISK ASSESSMENT; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; AZITHROMYCIN; BACTERIA; CEFTRIAXONE; COHORT STUDIES; COMMUNITY-ACQUIRED INFECTIONS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; FLUOROQUINOLONES; HUMANS; MALE; MIDDLE AGED; PNEUMONIA, BACTERIAL; RETROSPECTIVE STUDIES; RISK ASSESSMENT; YOUNG ADULT;

EID: 84899508293     PISSN: 01966553     EISSN: 15273296     Source Type: Journal    
DOI: 10.1016/j.ajic.2014.01.005     Document Type: Article

References (10)

1. L.A. Mandell, R.G. Wunderink, A. Anzueto, J.G. Bartlett, G.D. Campbell, and N.C. Dean et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults Clin Infect Dis 44 2007 S27 S72
2. J. Ruhe, and D. Mildvan Does empirical therapy with a fluoroquinolone or the combination of a β-lactam plus a macrolide result in better outcomes for patients admitted to the general ward? Infect Dis Clin North Am 27 2013 115 132
3. D.L. Paterson "Collateral Damage" from cephalosporin or quinolone antibiotic therapy Clin Infect Dis 38 2004 S341 S345
4. S.G. Weber, H.S. Gold, D.C. Hooper, A.W. Karchmer, and Y. Carmeli Fluoroquinolones and the risk for methicillin-resistant Staphylococcus aureus in hospitalized patients Emerg Infect Dis 9 2003 1415 1422
5. K.M. Wener, V. Schechner, H.S. Gold, S.B. Wright, and Y. Carmeli Treatment with fluoroquinolones or with β-lactam-β-lactamase inhibitor combinations is a risk factor for isolation of extended-spectrum-β- lactamase-producing Klebsiella species in hospitalized patients Antimicrob Agents Chemother 54 2010 2010 2016
6. C. Yip, M. Loeb, S. Salama, L. Moss, and J. Olde Quinolone use as a risk factor for nosocomial Clostridium difficile-associated diarrhea Infect Control Hosp Epidemiol 22 2001 572 575
7. E. Tacconelli, G. De Angelis, M.A. Cataldo, E. Mantengoli, T. Spanu, and A. Pan et al. Antibiotic usage and risk of colonization and infection with antibiotic-resistant bacteria: a hospital population-based study Antimicrob Agents Chemother 53 2009 4264 4269
8. T.P. Lodise, A. Kwa, L. Cosler, R. Gupta, and R.P. Smith Comparison of β-lactam and macrolide combination therapy versus fluoroquinolone monotherapy in hospitalized Veterans Affairs patients with community-acquired pneumonia Antimicrob Agents Chemother 51 2007 3977 3982
9. A.P. Magiorakos, A. Srinivasan, R.B. Carey, Y. Carmeli, M.E. Falagas, and C.G. Giske et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance Clin Microbiol Infect 18 2012 268 281
10. S. Upadhyay, and M.S. Niederman Biomarkers: what is their benefit in the identification of infection, severity assessment, and management of community-acquired pneumonia? Infect Dis Clin North Am 27 2013 9 31